Article info

Download PDFPDF
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
  1. Correspondence to:
    Dr Merete Lund Hetland
    Copenhagen University Hospital at Hvidovre, Department of Rheumatology 232, Kettegård Alle 30, DK 2650 Hvidovre, Denmark; merete.hetland{at}dadlnet.dk
View Full Text

Citation

Hjardem E, Østergaard M, Pødenphant J, et al
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

Publication history

  • Accepted March 10, 2007
  • First published March 27, 2007.
Online issue publication 
August 10, 2007

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.